242 related articles for article (PubMed ID: 1663726)
21. Successful treatment of an aciclovir-resistant herpes simplex type 2 infection with cidofovir in an AIDS patient.
Kopp T; Geusau A; Rieger A; Stingl G
Br J Dermatol; 2002 Jul; 147(1):134-8. PubMed ID: 12100196
[TBL] [Abstract][Full Text] [Related]
22. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
De Clercq E
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
De Clercq E; Holý A; Rosenberg I
Antimicrob Agents Chemother; 1989 Feb; 33(2):185-91. PubMed ID: 2719463
[TBL] [Abstract][Full Text] [Related]
24. (S)-1-(3-hydroxy-2-(phosphonylmethoxy)propyl)cytosine (HPMPC): a potent antiherpesvirus agent.
Bronson JJ; Ferrara LM; Hitchcock MJ; Ho HT; Woods KL; Ghazzouli I; Kern ER; Soike KF; Martin JC
Adv Exp Med Biol; 1990; 278():277-83. PubMed ID: 1963042
[No Abstract] [Full Text] [Related]
25. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections.
De Clercq E
Intervirology; 1997; 40(5-6):295-303. PubMed ID: 9675635
[TBL] [Abstract][Full Text] [Related]
26. Effects of phosphonylmethoxyalkyl derivatives studied with a murine model for abortion induced by equine herpesvirus 1.
Awan AR; Field HJ
Antimicrob Agents Chemother; 1993 Nov; 37(11):2478-82. PubMed ID: 8285638
[TBL] [Abstract][Full Text] [Related]
27. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
Neyts J; Snoeck R; Schols D; Balzarini J; De Clercq E
Virology; 1990 Nov; 179(1):41-50. PubMed ID: 2171213
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of the acquired immune deficiency syndrome (AIDS): acyclic nucleoside phosphonate analogues.
De Clercq E
Int J Immunopharmacol; 1991; 13 Suppl 1():91-8. PubMed ID: 1823910
[TBL] [Abstract][Full Text] [Related]
29. HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique.
Garneau M; Bolger GT; Bousquet C; Kibler P; Tremblay F; Cordingley MG
Antiviral Res; 2003 Aug; 59(3):193-200. PubMed ID: 12927309
[TBL] [Abstract][Full Text] [Related]
30. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Suruga Y; Makino M; Okada Y; Tanaka H; De Clercq E; Baba M
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):316-22. PubMed ID: 9704936
[TBL] [Abstract][Full Text] [Related]
31. Antivirals for the treatment of herpesvirus infections.
De Clercq E
J Antimicrob Chemother; 1993 Jul; 32 Suppl A():121-32. PubMed ID: 8407694
[TBL] [Abstract][Full Text] [Related]
32. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.
Kern ER; Collins DJ; Wan WB; Beadle JR; Hostetler KY; Quenelle DC
Antimicrob Agents Chemother; 2004 Sep; 48(9):3516-22. PubMed ID: 15328119
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Bronson JJ; Ghazzouli I; Hitchcock MJ; Webb RR; Martin JC
J Med Chem; 1989 Jul; 32(7):1457-63. PubMed ID: 2544723
[TBL] [Abstract][Full Text] [Related]
34. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
De Clercq E
Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
[TBL] [Abstract][Full Text] [Related]
35. Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections.
Smee DF; Sidwell RW; Barnett BB
Antiviral Res; 1996 Nov; 32(3):165-71. PubMed ID: 8955511
[TBL] [Abstract][Full Text] [Related]
36. Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection.
Scott RA; Pavesio C
Am J Ophthalmol; 2000 Jul; 130(1):126-7. PubMed ID: 11004276
[TBL] [Abstract][Full Text] [Related]
37. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
El-Haddad D; El Chaer F; Vanichanan J; Shah DP; Ariza-Heredia EJ; Mulanovich VE; Gulbis AM; Shpall EJ; Chemaly RF
Antiviral Res; 2016 Oct; 134():58-62. PubMed ID: 27582067
[TBL] [Abstract][Full Text] [Related]
38. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates.
Aduma P; Connelly MC; Srinivas RV; Fridland A
Mol Pharmacol; 1995 Apr; 47(4):816-22. PubMed ID: 7723743
[TBL] [Abstract][Full Text] [Related]
39. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
[TBL] [Abstract][Full Text] [Related]
40. The activity of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine (HPMPC) against equine herpesvirus-1 (EHV-1) in cell cultures, mice and horses.
Gibson JS; Slater JD; Field HJ
Antiviral Res; 1992 Sep; 19(3):219-32. PubMed ID: 1332605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
